marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2024
added 09-27-2025
Kamada Ltd. Total Non Current Liabilities 2011-2025 | KMDA
Annual Total Non Current Liabilities Kamada Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 7.06 M | 5.74 M | 2.17 M | 3.22 M | 5.75 M | 6.55 M | 7.7 M | 16.8 M | 31.5 M | 39.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.8 M | 2.17 M | 12.6 M |
Quarterly Total Non Current Liabilities Kamada Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 87.8 M | 8.32 M | - | - | 7.06 M | 6.42 M | - | - | 5.74 M | - | - | - | 2.17 M | - | - | - | 3.22 M | - | - | - | 5.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 87.8 M | 2.17 M | 15.8 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cellectis S.A.
CLLS
|
109 M | $ 4.3 | 12.57 % | $ 116 M |  France |
 |
Graybug Vision
GRAY
|
11 K | $ 0.44 | -11.23 % | $ 9.65 M |  USA |
 |
AgeX Therapeutics
AGE
|
1.53 M | $ 11.3 | -10.17 % | $ 12.2 K | - |
 |
Galera Therapeutics
GRTX
|
64 M | $ 0.14 | -32.59 % | $ 7.61 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
70.5 M | $ 2.52 | -1.18 % | $ 6.35 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
3.09 M | $ 4.37 | -1.58 % | $ 28.1 M |  China |
 |
Caladrius Biosciences
CLBS
|
254 K | $ 0.43 | -16.75 % | $ 25.8 M | USA |
 |
Sorrento Therapeutics
SRNE
|
299 M | $ 0.27 | -29.58 % | $ 126 M | USA |
 |
BeiGene, Ltd.
BGNE
|
374 M | $ 184.71 | 0.49 % | $ 251 B |  Cayman-islands |
 |
Midatech Pharma plc
MTP
|
110 K | $ 0.29 | -18.52 % | $ 27.3 M |  Britain |
 |
Aeterna Zentaris
AEZS
|
19.1 M | $ 5.72 | 5.93 % | $ 314 M |  Canada |
 |
ContraFect Corporation
CFRX
|
9.41 M | $ 1.47 | -5.16 % | $ 5.39 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
50.9 M | $ 4.93 | 1.02 % | $ 90.8 M | Britain |
 |
Advaxis
ADXS
|
16 M | $ 0.31 | -9.65 % | $ 45.9 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
5.04 M | $ 3.93 | -5.76 % | $ 99.8 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
148 M | $ 6.2 | - | $ 154 M | USA |
 |
Zymeworks
ZYME
|
2.86 M | $ 6.42 | - | $ 404 M | Canada |
 |
Kadmon Holdings, Inc.
KDMN
|
17.2 M | $ 9.5 | - | $ 1.7 B | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | $ 2.58 | -4.8 % | $ 255 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
4.49 M | $ 0.56 | 7.23 % | $ 2.72 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | $ 0.5 | - | $ 7.46 M |  Israel |
 |
Generation Bio Co.
GBIO
|
132 M | $ 6.33 | 1.61 % | $ 408 M | USA |
 |
Acceleron Pharma Inc.
XLRN
|
22.1 M | $ 179.68 | - | $ 10.9 B | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | $ 44.15 | -0.23 % | $ 916 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
25.2 M | $ 0.32 | - | $ 23.9 M | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
557 K | $ 18.44 | - | $ 1.94 B | Canada |
 |
Kaleido Biosciences
KLDO
|
22.2 M | $ 0.29 | -3.69 % | $ 12.4 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
704 K | $ 2.19 | - | $ 105 M | USA |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 1.35 | 2.27 % | $ 206 M | USA |
 |
ImmuCell Corporation
ICCC
|
13.2 M | $ 6.59 | 2.17 % | $ 53.8 M | USA |
 |
Humanigen
HGEN
|
2.34 M | $ 0.04 | -81.12 % | $ 4.28 M | USA |
 |
Aptinyx
APTX
|
114 K | $ 0.06 | -39.0 % | $ 4.57 M | USA |
 |
Tyme Technologies
TYME
|
4.89 M | $ 0.31 | 8.07 % | $ 54 M | USA |
 |
Keros Therapeutics
KROS
|
538 K | $ 15.96 | 1.98 % | $ 598 M | USA |
 |
Forward Pharma A/S
FWP
|
43 K | $ 2.64 | -0.75 % | $ 18.7 M |  Danmark |
 |
Krystal Biotech
KRYS
|
2.78 M | $ 187.18 | 2.27 % | $ 5.35 B | USA |
 |
Kymera Therapeutics
KYMR
|
157 M | $ 56.29 | -1.11 % | $ 4.22 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | $ 0.39 | - | $ 26.5 M | USA |
 |
Celyad Oncology SA
CYAD
|
23.3 M | $ 0.47 | - | $ 12.5 M |  Belgium |
 |
Brickell Biotech
BBI
|
146 K | $ 2.11 | -5.38 % | $ 6.06 M | USA |
 |
Genocea Biosciences
GNCA
|
64.5 M | $ 0.05 | -15.0 % | $ 3.04 M | USA |
 |
Codiak BioSciences
CDAK
|
119 M | $ 0.06 | -55.98 % | $ 2.15 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
17.9 M | $ 8.37 | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | $ 3.17 | 1.93 % | $ 17.4 M | USA |
 |
Calithera Biosciences
CALA
|
4.82 M | $ 0.37 | -10.95 % | $ 876 K | USA |
 |
Forma Therapeutics Holdings
FMTX
|
1.03 M | $ 20.01 | - | $ 958 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
52.2 M | $ 49.55 | -6.81 % | $ 3.04 B | USA |
 |
Sierra Oncology
SRRA
|
175 K | $ 54.89 | -0.05 % | $ 1.34 B | Canada |